Navigation Links
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced it will report third quarter 2011 financial results after the NASDAQ Global Market closes on November 3.  The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the third quarter as well as provide a corporate update.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and +1 (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Financial Results Call."  The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.  Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.  

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adults 18 years of age or older with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a t
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
10. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
11. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)... 2014 Continental Clinical Solutions, LLC ... clinical trials at its mid-Atlantic late-phase research facility, ... created with the idea of closing patient disparities ... in medical advances," said Continental's CEO, Saleh ... the immortal cell line of Henrietta Lacks, dubious ...
(Date:11/23/2014)... Apiscent Labs, a privately held ... ingredients to the global pharmaceutical and flavor & ... website, Apiscent.com. , The Apiscent.com homepage welcomes visitors ... easy navigation, rotating images and content focused on ... , The company’s work in Pharmaceutical ...
(Date:11/22/2014)... MD (PRWEB) November 21, 2014 ... management solutions provider, has released Limfinity® version 5.1.4. ... installation projects of Limfinity® than ever in RURO’s ... configuration and minority framework enhancement. Limfinity® version 5.1.4 ... far above and beyond bug fixes! , Limfinity® ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... even the resources of the world,s largest industrialized nations, scientists ... to find solutions. , Mark Shannon of the University of ... water resource research to address this crisis in a review ... "As dire as the growing problems are with a lack ...
... Blacksburg, Va. -- The ubiquity of mineral nanoparticles in ... intriguing properties provide Earth scientists with another dimension in ... team of scientists from seven universities in a review ... Nanominerals, Mineral Nanoparticles, and Earth Chemistry. , The way ...
... March 20 Scientists at the,Bio-Communications Research ... for,the Improvement of Human Functioning International (CIHFI), ... about its recent stem cell,discovery. The scientific ... stem cell population" received BioMed Central,s,Research Article ...
Cached Biology Technology:Countering an approaching water crisis 2Nanoscience will change the way we think about the world 2Nanoscience will change the way we think about the world 3Nanoscience will change the way we think about the world 4Nanoscience will change the way we think about the world 5Medical Research Award Goes to Adult Stem Cell Scientists at a Kansas Not-for-Profit Organization 2
(Date:11/11/2014)... -- Forensicon, Inc., a Chicago -based digital ... promotion of Yaniv Schiff from Senior Computer ... new role as Director, he will lead company efforts ... and provide leadership within the company,s digital forensics practice ... Schiff joined Forensicon in 2006 and ...
(Date:11/7/2014)... -- In conjunction with the Glendale and ... of the Verdugos has announced the " GLENDALE ... initiative to keep the Verdugo Regional Crime Lab operational after ... of existence, the Lab has processed more than 400 DNA ... "Because our number one priority is the wellbeing ...
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3
... of cell and developmental biology, has been awarded one ... Awards, one of the NIH,s most prestigious grants. ... address a significant medical science challenge: identifying the full ... and disease processes such as cancer. Major, a ...
... professors have been named 2010 fellows of the American ... and Interdisciplinary Studies (CBIS) and the Howard P. Isermann ... and Professor Emeritus of Chemistry Leonard Interrante were both ... and contributions to the science, the profession, and service ...
... parts of the world have brought into sharp focus new ... of rivers during periods of high flow. Using an ... how the flow of river water affects the movement of ... changes in the bed of an artificial water channel to ...
Cached Biology News:UNC scientist receives NIH director's New Innovator Award 2Rensselaer professors Dordick and Interrante named ACS Fellows 2What lies beneath: Study examines sediment movement during floods in rivers 2What lies beneath: Study examines sediment movement during floods in rivers 3
...
... Conjugation Kits are based on well-established ... are consistent and reproducible. This kit ... your protein or antibody, including ready-to-use ... Activated HRP is supplied ready-to-use ...
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... PCR detection system holds 48 x 0.2 ml ... 48 LEDs independently excites fluorescence (470-500 nm) for ... detects emitted light (523-543 nm and 540-700 nm). ... cycler, whose Peltier heat pumps provide superb thermal ...
Biology Products: